Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN V POTASSIUM versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN V POTASSIUM versus PENICILLIN 2.
PENICILLIN V POTASSIUM vs PENICILLIN-2
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Penicillin V is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and activating autolytic enzymes.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Treatment of mild to moderate infections caused by susceptible organisms: streptococcal pharyngitis, scarlet fever, pneumococcal infections, skin and soft tissue infections, and as prophylaxis for rheumatic fever recurrence.Off-label: Lyme disease (early localized), actinomycosis, anthrax (post-exposure prophylaxis), and prevention of bacterial endocarditis in dental procedures.
Streptococcal infectionsPneumococcal infectionsMeningococcal infectionsSyphilisLyme diseaseAnthraxActinomycosisProphylaxis for rheumatic fever
250-500 mg orally every 6-8 hours.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
0.5-1 hour in patients with normal renal function; prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min). Clinical context: requires frequent dosing due to short half-life.
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Primarily excreted unchanged by the kidneys; minor hepatic metabolism to penicilloic acid.
Primarily eliminated unchanged by renal tubular secretion; minor hepatic metabolism to penicilloic acid.
Renal excretion of unchanged drug accounts for 20-40% of the dose via glomerular filtration and tubular secretion; biliary excretion is minor (<1%). Fecal elimination is negligible.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
60-80% bound to serum albumin; binding is saturable at high concentrations.
50-65% bound, primarily to albumin
0.3-0.5 L/kg; approximates extracellular fluid volume; limited penetration into CSF unless meninges inflamed.
0.3-0.5 L/kg; low Vd indicates limited tissue penetration
Oral: 60-70% (variable, decreased by food); absorption is reduced in achlorhydria.
Oral: 60-70% (decreased with food); IM: 70-85%
CrCl 10-50 mL/min: 250-500 mg every 8-12 hours; CrCl <10 mL/min: 250-500 mg every 12-18 hours.
For CrCl 10-50 mL/min: administer every 8-12 hours; for CrCl <10 mL/min: administer every 12-18 hours; hemodialysis: give after dialysis.
No dosage adjustment required for Child-Pugh Class A, B, or C.
No specific Child-Pugh based dose adjustment; use with caution in severe hepatic impairment.
Children >12 years: 250-500 mg orally every 6-8 hours; Children 1-12 years: 25-50 mg/kg/day orally divided every 6-8 hours; Infants <1 year: 25-50 mg/kg/day orally divided every 6-8 hours.
For children >1 month: 25-50 mg/kg/day orally divided every 6-8 hours; severe infections: 100-250 mg/kg/day IV divided every 4-6 hours; maximum 12 g/day.
No specific dose adjustment; consider renal function and monitor for adverse effects.
No specific dose adjustment except for renal function; monitor renal function and adjust dose accordingly.
No FDA black box warnings.
No FDA black box warning.
Serious hypersensitivity reactions including anaphylaxis; use with caution in renal impairment; avoid in patients with mononucleosis due to high risk of rash; prolonged use may lead to superinfection; Clostridium difficile-associated diarrhea possible.
["Hypersensitivity reactions including anaphylaxis","Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome)","Clostridioides difficile-associated diarrhea","Renal impairment requiring dose adjustment","Neurologic toxicity with high doses (seizures)"]
Hypersensitivity to penicillins; infectious mononucleosis (relative contraindication due to risk of maculopapular rash).
["Hypersensitivity to penicillins","History of severe immediate hypersensitivity reaction to beta-lactam antibiotics"]
Data Pending Review
Data Pending Review
Avoid taking with food, especially acidic foods (e.g., citrus, soda) or fruit juices, as they may reduce absorption. Take on an empty stomach with water only. No specific drug-food interactions noted beyond absorption effects.
No significant food interactions. Can be taken with or without food.
Penicillin V potassium is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. It is generally considered safe throughout all trimesters, as penicillins are not associated with teratogenic effects. No increased risk of congenital malformations has been observed with first-trimester exposure.
Penicillin is generally considered low risk; no significant teratogenic effects have been consistently reported in first trimester. Animal studies show no fetal harm. Use is considered safe across all trimesters when indicated.
Penicillin V potassium is excreted into breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.2. It is considered compatible with breastfeeding, as it is unlikely to cause adverse effects in the nursing infant. However, theoretical risks include alteration of infant gut flora and allergic sensitization. Monitoring for diarrhea or rash in the infant is advisable.
Penicillin is excreted into breast milk in low concentrations (M/P ratio approximately 0.2). It is compatible with breastfeeding; no adverse effects on nursing infants reported. Caution in infants with history of penicillin allergy.
No dose adjustment is typically required during pregnancy. Physiologic changes (e.g., increased renal blood flow and glomerular filtration rate) may increase clearance of penicillin, but data are limited and dose modifications are not routinely recommended for standard infections. For severe infections or in patients with inadequate response, consider monitoring serum levels or adjusting dose based on clinical response and renal function.
Increased renal clearance in pregnancy may reduce serum concentrations; higher doses may be required for severe infections, but standard dosing is generally adequate. No specific dose adjustment is uniformly recommended; monitor clinical response.
Category A/B
Category C
Penicillin V potassium is acid-stable, allowing oral administration; it is first-line for group A streptococcal pharyngitis and prophylaxis for rheumatic fever. Take on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption. Use with caution in renal impairment; adjust dose if CrCl <10 mL/min. Monitor for hypersensitivity reactions, including anaphylaxis, especially in patients with beta-lactam allergy. Not effective against beta-lactamase-producing organisms.
Penicillin-2 (benzathine penicillin G) is indicated for syphilis and group A streptococcal infections. Intramuscular injection only; avoid intravenous administration. Monitor for Jarisch-Herxheimer reaction. Dose adjustment in renal impairment is not typically required due to slow release.
Take this medication exactly as prescribed, even if you feel better.Take on an empty stomach with a full glass of water, 1 hour before or 2 hours after meals.Complete the full course of treatment to prevent resistance.Do not skip doses; if you miss a dose, take it as soon as remembered unless it is near time for next dose.Seek immediate medical attention if you experience rash, hives, difficulty breathing, or swelling of face/mouth.Inform your doctor if you have history of allergies, especially to penicillins or cephalosporins.This medication may cause diarrhea; contact your doctor if severe or persistent.Store at room temperature away from moisture and heat.
Complete the full course as prescribed, even if symptoms improve.Report any rash, difficulty breathing, or swelling immediately.Avoid alcohol during treatment to minimize side effects.Do not stop or change the dose without consulting your doctor.Inform all healthcare providers about this therapy.